English (international)
Eesti
Български
Deutsch
Français
Español (Latinoamérica)
Polski
Magyar
Română
BioCryst Pharmaceuticals Inc
Closed
Sector Healthcare
7.83 3.71
Overview
Share price change
24h
Min
7.52
Max
7.84
Income | -36M |
|---|---|
Sales | 6.7M 93M |
EPS | -0.28 |
Profit margin | -41.674 |
Employees | 536 |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +105.3 upside |
Next Earnings | 5 sie 2024 |
|---|
Market Cap | 41M 990M |
|---|---|
Previous open | 4.12 |
Previous close | 7.83 |
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
BioCryst Pharmaceuticals Inc Chart
Related News
Peer Comparison
Price change
BioCryst Pharmaceuticals Inc Forecast
Price Target
By TipRanks
105.3% upside
12 Months Forecast
Average 15.5 USD 105.3%
High 30 USD
Low 6 USD
Based on 8 Wall Street analysts offering 12 month price targets forBioCryst Pharmaceuticals Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc. discovers oral and small-molecule medicines that treat rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The Company has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.
